Limbach Group Adopts QuantaMatrix dRAST in Routine Clinical Use
December 14, 2021 at 06:39 pm EST
Share
QuantaMatrix announced that its dRASTTM platform has been adopted for routine use by the Limbach Group, a German-based laboratory group, for the benefit of patients, clinical laboratories and clinicians. This successful deployment is the result of a partnership between QuantaMatrix Europe, a fully owned affiliate of QuantaMatrix Inc., based in Paris (France), and Axonlab, one of the leading in vitro diagnostics solution providers in Europe. Following the successful validation of the dRAST platform by major reference laboratories in Europe, QuantaMatrix partnered with Axonlab to promote its use in Germany, Switzerland, Austria and the Benelux region, alongside other European countries. An initial agreement with the Limbach Group in Germany means the dRAST solution is now available to the maximum number of that nation's sepsis patients. The Limbach Group was created from the merger of independent laboratories throughout Germany. As the country's largest owner-managed laboratory group, it covers the entire spectrum of lab diagnostics with more than 30 clinical laboratories throughout the nation. MVZ Labor Ravensburg is one of the major labs within the Limbach Group and has adopted dRAST in routine clinical use.
QuantaMatrix Inc is a Korean-based company engaged in the development and production of in vitro diagnostics (IVD) medical devices. The Company's main products include a multi-diagnostic unique test platform, micro disc, antimicrobial susceptibility testing sepsis diagnostic equipment, molecular immunity diagnosis automation platform, rapid antituberculosis susceptibility testing equipment, rapid antituberculosis susceptibility testing kits, and others. In addition, the Company sells covid kits and engages in research and development of microbial diagnostic products.